GSK (GSK) Q2 2026 earnings review
Core Operations Hold Steady, But a Massive Pipeline Failure Torpedoes GAAP Earnings
GSK's Q2 2026 tells a tale of two income statements. Core operations performed admirably: Sales grew 5% (CER) to £8.4B, driven by 14% growth in Specialty Medicines, and Core Operating Profit rose 7%. However, Total (GAAP) EPS collapsed 69% YoY. The culprit? A massive £1.3 billion impairment charge after the highly anticipated chronic cough drug, camlipixant, failed its Phase III trials. Management has immediately pivoted, announcing a £2.4 billion restructuring program to cut costs and aggressively acquire new late-stage assets like Nuvalent for $10.6B. While 2026 Core guidance was reaffirmed at the upper end of the 3-5% revenue growth range, the destruction of a key pipeline asset raises serious questions about the company's long-term £40B revenue target.
🐂 Bull Case
The Specialty division continues to do the heavy lifting, growing 14% in Q2. The HIV long-acting portfolio is dominating its market segment, with Cabenuva (+33%) and Apretude (+39%) driving high-margin volume.
Management isn't crying over spilled milk. They immediately wrote off camlipixant, launched a £1.9 billion annual savings initiative to reallocate capital, and closed the $10.6B acquisition of Nuvalent to restock the oncology pipeline.
🐻 Bear Case
The £1.3B write-off of camlipixant is a severe blow. Management vigorously defended this asset's trial design against analyst skepticism just last year. Its failure injects significant execution risk into their 2031 revenue targets.
General Medicines are acting as a heavy anchor, shrinking 9% this quarter. US Medicare Part D redesign and pricing pressures crushed Trelegy (-7%), a trend that is expected to persist.
⚖️ Verdict: ⚪
Neutral. Underlying cash flow and core operations remain highly cash-generative, and the prompt restructuring shows aggressive leadership. However, the camlipixant failure destroys significant future value, leaving the company heavily reliant on recently acquired assets to bridge the upcoming 2028 dolutegravir patent cliff.
Key Themes
The Camlipixant Disaster
A staggering £1.33 billion impairment charge was recorded after GSK abandoned camlipixant for refractory chronic cough due to poor Phase III CALM-1/2 data. This contradicts management's defensive posturing on the Q2 2025 call, where they insisted the trials were "on track" and deliberately enriched to avoid competitor Merck's pitfalls. This failure, compounded by a £371M impairment on terminated Alector collaboration assets, caused Total R&D expenses to spike 71% YoY and crushed GAAP operating profit.
Funding the Pivot: 'Accelerate Growth' Programme
To recover from R&D setbacks and navigate the 2028-2030 dolutegravir loss of exclusivity, GSK announced a massive 3-year restructuring effort. Costing £2.4B upfront, it targets £1.9B in annual savings by 2029. Management explicitly stated these savings will fund a late-stage pipeline acceleration (targeting 20+ phase III trial starts in 2026) and stabilize operating margins during the patent cliff. This is a clear, aggressive capital reallocation strategy.
Long-Acting HIV Franchise Securing the Future
The HIV segment is successfully executing its transition from daily pills to long-acting injectables (LAIs). Cabenuva (£453M, +33%) and Apretude (£140M, +39%) drove 80% of total HIV growth in Q2. LAIs now represent 35% of US HIV turnover. This mix shift is crucial for preserving pricing power and patient lock-in ahead of upcoming patent cliffs.
General Medicines Headwinds Worsen
General Medicines continue to decelerate, falling 9% in Q2. The macro environment in the US is the primary culprit: Medicare Part D benefit redesign and aggressive channel mix pricing adjustments severely hampered Trelegy, which fell 7% (£775M). Management expects this portfolio to remain a drag, guiding for a mid-to-low single-digit decline for the full year.
Aggressive Oncology M&A: Nuvalent
Recognizing gaps in the pipeline, GSK deployed $10.6B (£8.0B) in July 2026 to acquire Nuvalent. This secures zidesamtinib (a ROS1 inhibitor recently FDA approved) and neladalkib (an ALK inhibitor under FDA review). This aggressive, post-quarter M&A directly injects de-risked, late-stage commercial assets into the Oncology segment, which grew 17% this quarter but saw legacy asset Zejula collapse by 34%.
Other KPIs
Despite the massive hit to GAAP net income, free cash flow surged 77% YoY. This confirms that the quarter's profitability collapse was entirely driven by non-cash accounting impairments rather than operational degradation. Cash generation from operations reached £2.9B, aided by favorable timing of trade receivables and proceeds from the divestment of linerixibat.
Stable. Core margins expanded by 0.4 percentage points YoY. This was achieved through a highly favorable product mix shift toward Specialty Medicines and higher-margin Vaccines in Europe, which drove Cost of Sales as a percentage of revenue down by 2.3 ppts to 22.6%. This operational leverage successfully offset increased R&D spend.
Guidance
Stable. Management reaffirmed guidance but specified they expect to land in the upper half of the range. Specialty Medicines are guided to grow low double-digits, while General Medicines are explicitly guided to decline mid-to-low single-digits.
Decelerating vs FY25's double-digit pace, but stable relative to current expectations. The company is actively accelerating productivity initiatives to offset increased R&D pipeline investments, expecting SG&A to remain broadly stable.
Decelerating. While operating profit will hit the high end, EPS will be constrained to the lower half of the 7-9% range. This is due to a structural increase in the effective tax rate (rising to ~17.5%) and roughly £800M in higher interest charges, driven heavily by the new debt taken on for the $10.6B Nuvalent acquisition.
Key Questions
Bridging the Pipeline Gap
With the failure of camlipixant (previously touted as a major growth driver), how does this alter the math for achieving the >£40B 2031 revenue target, and is the Nuvalent acquisition sufficient to fill that specific revenue hole?
Accelerate Growth Reinvestment
The 'Accelerate Growth' program aims for £1.9B in savings to reinvest in R&D and margins. Given recent Phase III failures, what changes are being made to clinical oversight to ensure this newly freed capital isn't burned on poorly performing assets?
Trelegy and US Pricing Floor
General Medicines fell 9% due to US Medicare Part D redesign and channel pricing on Trelegy. Has this pricing pressure bottomed out, or should we expect these structural US headwinds to compound in 2027?